Thank you Sam! Looking great! One quick question... is that the correct number for the percentage of refills for the sector? You have AMRN up 4.22%, much more so than GenL or L, but the sector you have as up 4.35% from last week. If that is correct, how is it calculated?
I expect once the the word is out during and after AHA meeting, about EPA being the key component to reducing risk of CVD. Lovaza and Generic Lovaza scripts will be in decline. We will be the premier drug on this list you provide.